First quantitative study of "Ozempic face" shows 7% midfacial volume loss per 10 kg of weight loss | Research

The takeaway

In 20 patients with before/after CT/MR imaging, GLP-1 agonist use resulted in a median 9% total midfacial volume decrease, primarily in superficial fat pads, with 7% volume loss per 10 kg of body weight lost.

7% facial volume per 10 kg lost
First quantitative measurement of "Ozempic face" showing superficial midfacial fat is preferentially lost during GLP-1-mediated weight loss

What the researchers found

Median total midfacial volume decreased 9%, superficial 11%, deep 7%. Superficial volume loss correlated with weight loss (rho=0.590, p=0.006). Linear regression: 7% facial volume loss per 10 kg weight loss (p=0.029). Deep volume loss did not correlate with weight.

Why it matters

Millions are experiencing facial changes on GLP-1 drugs but until now there was no objective measurement. This study quantifies the "Ozempic face" phenomenon and shows it primarily affects superficial fat, which is important for facial rejuvenation planning.

How the study worked

Retrospective cohort study at a tertiary academic center. 20 patients with GLP-1 prescriptions and head/neck CT/MR imaging before and after treatment (2017-2024). Midface volume measurements of total, superficial, and deep compartments.

What this study cannot tell us

Very small sample (n=20). Retrospective design. Imaging was obtained for other clinical indications, not standardized. No control group (weight loss from other causes). Cannot distinguish drug effect from weight loss effect.

How to read the evidence

Small retrospective cohort with objective radiographic measurements. Provides first quantitative data but limited by sample size and lack of controls.

When this study was published

Published in 2025; first objective radiographic assessment of GLP-1-associated facial volume changes.

The bigger picture

As GLP-1 drug use expands, the cosmetic and psychological impact of facial volume loss becomes increasingly relevant. Understanding that superficial fat is preferentially lost helps facial plastic surgeons plan filler and fat transfer treatments to restore a youthful appearance.

Questions still open

Is facial volume loss with GLP-1 drugs reversible if weight is regained?
Do some GLP-1 drugs cause more facial deflation than others?
Can resistance exercise or protein intake preserve facial fat during GLP-1 treatment?

Common questions

What is Ozempic face?

"Ozempic face" refers to the facial deflation and premature aging appearance that can occur with significant weight loss from GLP-1 drugs. This study measured it objectively for the first time, finding an average 9% loss in midfacial volume, primarily from superficial fat pads that provide a youthful, full appearance.

Can Ozempic face be treated?

Yes. Facial plastic surgeons can restore lost volume using dermal fillers or fat transfer procedures. Understanding that superficial fat is preferentially lost helps guide treatment. However, prevention through gradual weight loss and adequate nutrition may help minimize facial changes.

Read the original research

Radiographic Midfacial Volume Changes in Patients on GLP-1 Agonists.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 173(2), 360-366

View on PubMed ↗Publisher’s paper ↗

Citation

Sharma, Rahul K; Vittetoe, Kelly L; Barna, Alexander J; Takkouche, Sahar; Varelas, Antonios N; Yang, Shiayin F; Stephan, Scott J; Patel, Priyesh N. (2025). Radiographic Midfacial Volume Changes in Patients on GLP-1 Agonists.. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 173(2), 360-366. https://doi.org/10.1002/ohn.1209